Ocular HSV-1:construction and analysis of AL mutants
眼部HSV-1:AL突变体的构建和分析
基本信息
- 批准号:6796217
- 负责人:
- 金额:$ 4.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-08-01 至 2006-07-31
- 项目状态:已结题
- 来源:
- 关键词:antisense nucleic acidblindnessfunctional /structural genomicsgene targetinggenetically modified animalsherpes simplex virus 1laboratory rabbitlatent virus infectionocular herpesphenotypepostdoctoral investigatorprotein structure functionteartissue /cell culturetranscription factorvirulencevirus geneticsvirus infection mechanism
项目摘要
DESCRIPTION (provided by applicant): Recurrent HSV-I, due to reactivation of latent virus from sensory neurons, is a major cause of corneal blindness. LAT, the only viral transcript thought to be made during latency, is essential for efficient reactivation. Recently, a new viral transcript, AL, was found during latency. AL is anti-sense to LAT and produces a protein in infected rabbits. Since AL and LAT overlap, phenotypes previously attributed to LAT may be due to AL. Two hypotheses will be tested: AL plays a role in (1) spontaneous reactivation; and (2) virulence. My specific aim is to determine the function of AL. AL-/LAT + and AL+/LAT - mutants will be constructed and their reactivation and virulence phenotypes analyzed in the rabbit ocular model. These complementary mutants should allow us to determine if AL is involved in spontaneous reactivation and/or virulence, or if both phenotypes are due solely to LAT. This information will be critical to the development of novel strategies to reduce recurrent viral reactivation and conseequently reduce HSV-1 induced eye disease.
描述(由申请方提供):由于感觉神经元中潜伏病毒的再激活,复发性HSV-I是角膜失明的主要原因。 LAT是唯一被认为在潜伏期产生的病毒转录物,对于有效的再激活至关重要。最近,在潜伏期发现了一种新的病毒转录本AL。AL是LAT的反义,并在感染的兔子中产生一种蛋白质。由于AL和LAT重叠,以前归因于LAT的表型可能是由于AL。将检验两个假设:AL在(1)自发再激活和(2)毒力中起作用。本研究的具体目的是确定AL的功能。将构建AL-/LAT +和AL+/LAT -突变体,并在兔眼模型中分析它们的再激活和毒力表型。这些互补的突变体应该使我们能够确定AL是否参与自发的再激活和/或毒力,或者这两种表型是否仅由LAT引起。这些信息对于开发新的策略以减少复发性病毒再激活并因此减少HSV-1诱导的眼病至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID J BRICK其他文献
DAVID J BRICK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID J BRICK', 18)}}的其他基金
Ocular HSV-1:construction and analysis of AL mutants
眼部HSV-1:AL突变体的构建和分析
- 批准号:
6927819 - 财政年份:2003
- 资助金额:
$ 4.89万 - 项目类别:
Ocular HSV-1:construction and analysis of AL mutants
眼部HSV-1:AL突变体的构建和分析
- 批准号:
6694910 - 财政年份:2003
- 资助金额:
$ 4.89万 - 项目类别:
相似国自然基金
盲人脑网络可塑性的磁共振影像研究
- 批准号:30900476
- 批准年份:2009
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Prime editing for Crumbs homologue 1 (CRB1) Inherited Retinal Dystrophies
Crumbs 同源物 1 (CRB1) 遗传性视网膜营养不良的 Prime 编辑
- 批准号:
10636325 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Development of a novel depot delivery system for a glaucoma therapeutic
开发用于青光眼治疗的新型储库递送系统
- 批准号:
10699791 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Planning the VICTORY (VIsual ComplicaTions Of PrematuRitY) Study
规划 VICTORY(早产儿视觉并发症)研究
- 批准号:
10645471 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser Ophthalmology
双光子扫描激光眼科评价青光眼 RGC 的体内功能和代谢
- 批准号:
10660761 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Reversal of Ovarian Aging in Mice Through AAV-mediated Oocyte Reprogramming in vivo
通过 AAV 介导的体内卵母细胞重编程逆转小鼠卵巢衰老
- 批准号:
10723227 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
新型聚合物-抗体缀合物作为眼部疾病的长效治疗药物
- 批准号:
10760186 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Genome Editing Therapy for Usher Syndrome Type 3
针对 3 型亚瑟综合症的基因组编辑疗法
- 批准号:
10759804 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
- 批准号:
10726508 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Personalizing Circumpapillary Retinal Nerve Fiber Layer Thickness Norms for Glaucoma
个性化青光眼环视乳头视网膜神经纤维层厚度标准
- 批准号:
10728042 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:
Mechanisms of structural plasticity, client interactions, and co-aggregation of the lens ⍺-crystallins
晶状体α-晶状体的结构可塑性、客户相互作用和共聚集机制
- 批准号:
10709482 - 财政年份:2023
- 资助金额:
$ 4.89万 - 项目类别:














{{item.name}}会员




